226 related articles for article (PubMed ID: 32695719)
1. Hydroxychloroquine in Dermatology and Beyond: Recent Update.
Sardana K; Sinha S; Sachdeva S
Indian Dermatol Online J; 2020; 11(3):453-464. PubMed ID: 32695719
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Bansal P; Goyal A; Cusick A; Lahan S; Dhaliwal HS; Bhyan P; Bhattad PB; Aslam F; Ranka S; Dalia T; Chhabra L; Sanghavi D; Sonani B; Davis JM
Ann Med; 2021 Dec; 53(1):117-134. PubMed ID: 33095083
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine in dermatology: New perspectives on an old drug.
Chew CY; Mar A; Nikpour M; Saracino AM
Australas J Dermatol; 2020 May; 61(2):e150-e157. PubMed ID: 31612996
[TBL] [Abstract][Full Text] [Related]
5. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
6. [Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19].
Morgado-Carrasco D; Ibaceta-Ayala J; Piquero-Casals J
Actas Dermosifiliogr; 2022 Feb; 113(2):166-175. PubMed ID: 34366433
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19.
Morgado-Carrasco D; Ibaceta-Ayala J; Piquero-Casals J
Actas Dermosifiliogr; 2021 Nov; ():. PubMed ID: 34848889
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine and COVID-19.
Sinha N; Balayla G
Postgrad Med J; 2020 Sep; 96(1139):550-555. PubMed ID: 32295814
[TBL] [Abstract][Full Text] [Related]
11. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
12. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Gagnon LR; Sadasivan C; Yogasundaram H; Oudit GY
Curr Heart Fail Rep; 2022 Dec; 19(6):458-466. PubMed ID: 36167917
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Meo SA; Klonoff DC; Akram J
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
[TBL] [Abstract][Full Text] [Related]
14. Treatment of COVID 19-Repurposing drugs commonly used in dermatology.
Stojkovic-Filipovic J; Bosic M
Dermatol Ther; 2020 Sep; 33(5):e13829. PubMed ID: 32542964
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Khuroo MS
Int J Antimicrob Agents; 2020 Sep; 56(3):106101. PubMed ID: 32687949
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
Stremmel C; Kellnar A; Massberg S; Kääb S
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):497-502. PubMed ID: 32700555
[TBL] [Abstract][Full Text] [Related]
17. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
18. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
Patil VM; Singhal S; Masand N
Life Sci; 2020 Aug; 254():117775. PubMed ID: 32418894
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Pothen L; Yildiz H; Samnick MM; Yombi JC
Clin Rheumatol; 2021 Apr; 40(4):1649-1657. PubMed ID: 33452660
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
